Go to Market Strategy

Our bespoke and crafted go-to-market strategies are a key part of our commercialisation solution for those seeking to bring a rare disease medicine or product to market in Europe. Leveraging a scientific approach, we delve deeply into our partners’ products, value propositions, and their overarching objectives to develop a winning strategy that delivers for patients, practitioners, and the asset owner equally. The result is a profitable strategy that meets market needs and satisfies patient demands.

How we work

Our method involves conducting a comprehensive situational analysis for each targeted market, validating the core strategic assumptions with empirical data and insights from industry experts. We identify the best sources of data and assess the situation in the market to establish its size, and to understand the unmet need in the market itself. In situations where there is little information available, something that we often experience in rare disease medicine, we use our on the ground teams to gain access to local key opinion leaders in the relevant markets and develop a proposition built on their scientific knowledge and data.

Along with gathering information on the treatment side, we consider the pricing and access situations of the relevant markets, taking into account the different terms of reimbursement and pricing that countries can charge in different territories across Europe, along with affordability concerns. This all ensures that the strategies and directives we develop are in perfect harmony with our partners’ visions while being finely tuned to the nuances of the local market environment. 

Additionally, we are across the regulatory environment, ensuring that the new drug or treatment meets all compliance requirements before launch.  

Developing a strong value proposition

With this understanding of the market to underpin it, we develop a strong value proposition speaking to efficacy and outcomes that will deliver the best possible reimbursement in the markets where it matters. Having a strong core story about the value of the treatment is essential: we work hard to create this core communication asset that can be used to demonstrate value across all areas, showing key benefits to payers, physicians, and patients in all the different aspects.

This can be a complex situation to achieve with a range of different criteria employed in different markets: with our years of experience working across reimbursed markets, we are aware of the different ways that payers evaluate drugs and know which arguments are the most convincing in each market. We fully understand how your drug adds value, what its key points of difference are for the market in question, and communicate it in the most successful way, giving your drug the strongest possible chance of success.